Indications
Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1).
Composition
- Active substance
- inebilizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Uplizna
- Active substance
- inebilizumab
- ATC code
- L04AA
- Therapeutic area
- Neuromyelitis Optica
- Marketing authorisation holder
- Amgen Europe B.V.
- Status
- Authorised